Translational cancer research最新文献

{"title":"Oncogenic role and prognostic significance of PIMREG in melanoma.","authors":"Xiao Wei, Yujia Jiang, Tianxiang Xia, Jun Du","doi":"10.21037/tcr-24-1861","DOIUrl":"10.21037/tcr-24-1861","url":null,"abstract":"<p><strong>Background: </strong>Phosphatidylinositol binding clathrin assembly protein interacting mitotic regulator (PIMREG) plays a significant role in metaphase-to-anaphase transition in cell cycle. Its aberrant expression has been reported to be in correlation with the development of several tumors. However, its role in melanoma remains unknown. This study aimed to investigate the diagnostic and prognostic roles of PIMREG in skin cutaneous melanoma (SKCM).</p><p><strong>Methods: </strong>The expression levels of PIMREG were analyzed in SKCM using datasets downloaded from The Cancer Genome Atlas (TCGA), Genotype-Tissue Expression (GTEx), and Gene Expression Omnibus (GEO). The diagnostic accuracy was assessed using the receiver operating characteristic (ROC) curve. PIMREG was correlated to the functional states of SKCM cells using CancerSEA. Additionally, a protein-protein interaction network was constructed using STRING (https://cn.string-db.org), and hub genes were identified using Cytoscape. Enrichment analysis through Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG), and Gene Set Enrichment Analysis (GSEA) was utilized to explore the potential functions of PIMREG. The single-sample GSEA (ssGSEA) method was employed to investigate the correlation between PIMREG expression and the level of immune infiltration in SKCM. Drug sensitivity and resistance were analyzed using GSCALite and Cellminer.</p><p><strong>Results: </strong>The expression of PIMREG was significantly higher in SKCM tissues. Its overexpression correlated with poor survival outcome in melanoma patients. ROC analysis also revealed that PIMREG had high diagnostic potential, with area under the ROC curve (AUC) value of 0.874. Multivariate regression also identified PIMREG could serve as an independent diagnostic indicator for SKCM. Using the web tool of CancerSEA, we demonstrated that PIMREG is involved in cell cycle, DNA repair, DNA damage, epithelial-mesenchymal transition (EMT), invasion, and proliferation. Functional enrichment analysis revealed that PIMREG might be correlated with some biological processes (BPs) and important pathways related to cancer, including Wnt signaling and epidermis development.</p><p><strong>Conclusions: </strong>PIMREG is a promising diagnostic and prognostic biomarker and may be regarded as a possible therapeutic target for SKCM.</p>","PeriodicalId":23216,"journal":{"name":"Translational cancer research","volume":"14 2","pages":"1070-1084"},"PeriodicalIF":1.5,"publicationDate":"2025-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11912051/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143658239","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"PRSS3 is a potential prognostic biomarker for lung adenocarcinoma.","authors":"Lu Nie, Xueqing Zhang, Jie Wu","doi":"10.21037/tcr-24-1556","DOIUrl":"10.21037/tcr-24-1556","url":null,"abstract":"<p><strong>Background: </strong>Lung adenocarcinoma (LUAD) is a highly prevalent and deadly form of lung cancer and is a significant health concern worldwide. Although the expression of serine protease 3 (PRSS3) is elevated in certain cancers, its function in LUAD is yet unclear. The aim of this study was to investigate the mechanism of PRSS3 in lung adenocarcinoma, and validate PRSS3 as a reliable prognostic biomarker in lung adenocarcinoma.</p><p><strong>Methods: </strong>The Cancer Genome Atlas (TCGA) provides RNA expression data and patient medical information for LUAD patients. To determine which genes are expressed differently in LUAD and normal lung tissues, we carefully examined these data. We then used Cox regression analysis to examine the expression and survival data to pinpoint the genes that are strongly associated with patient survival. The PRSS3 gene affects patient prognosis. Afterward, we divided LUAD patients into low- and high-expression groups on the basis of the median PRSS3 expression to examine the relationship between immune cells and PRSS3. The results of the CIBERSORT and CIBERSORTx studies revealed correlations between PRSS3 and the degree of infiltration of several immune cell types. After the groups with low and high PRSS3 expressions were compared, PRSS3-related genes were identified, and functional enrichment analysis was performed. Furthermore, a model was developed to predict patient prognosis according to clinical characteristics and PRSS3 expression. After the bioinformatics analyses were completed, we validated the differential expression of PRSS3 in samples obtained from our center via Western blotting and immunohistochemistry (IHC).</p><p><strong>Results: </strong>We found that PRSS3 expression is highly upregulated in LUAD and that high PRSS3 expression is associated with a poorer prognosis in the TCGA database. Single-sample gene enrichment analysis revealed a strong correlation between PRSS3 and the immunological microenvironment. The clinical model developed on the basis of the PRSS3 showed great accuracy and can be used as a significant diagnostic indicator for LUAD. Western blotting and IHC confirmed a substantial increase in PRSS3 expression in LUAD. Herein, we analyzed an available dataset for a clinical cohort and revealed that elevated levels of PRSS3 are indicative of unfavorable outcomes in patients diagnosed with LUAD.</p><p><strong>Conclusions: </strong>PRSS3 is significantly upregulated in LUAD and can be used as a marker for LUAD diagnosis and prognosis assessment. Further study of PRSS3 could provide valuable insight into the mechanisms underlying the occurrence and progression of LUAD.</p>","PeriodicalId":23216,"journal":{"name":"Translational cancer research","volume":"14 2","pages":"1124-1140"},"PeriodicalIF":1.5,"publicationDate":"2025-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11912035/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143658422","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Characterization of immune landscape and prognostic value of IL-17-related signature in invasive breast cancer.","authors":"Wenge Dong, Xiaojie Gu, Jiejing Li, Zhigang Zhuang","doi":"10.21037/tcr-24-1632","DOIUrl":"10.21037/tcr-24-1632","url":null,"abstract":"<p><strong>Background: </strong>Recently, interleukin 17 (IL-17) has been found to play a critical role in the development of breast cancer. However, its prognostic significance in invasive breast cancer (IBC) remains unclear. This study aims to determine the role of IL-17-related signatures in IBC to identify novel therapeutic options.</p><p><strong>Methods: </strong>IBC data from The Cancer Genome Atlas (TCGA), Gene Expression Omnibus (GEO), and Molecular Taxonomy of Breast Cancer International Consortium (METABRIC) were used to identify IL-17-related prognostic genes. A predictive model was developed using TCGA data and validated using METABRIC data. The relationship between IL-17 scores and immune landscape, chemotherapy drug sensitivity [half maximal inhibitory concentration (IC50)], and immune checkpoint gene expression was analyzed. The quantitative reverse transcription polymerase chain reaction (qRT-PCR) was performed to validate key gene expression in breast tumor and normal tissue samples.</p><p><strong>Results: </strong>The predictive model identified core IL-17-related prognostic genes and successfully estimated the prognosis of IBC patients. The model's validity was confirmed using METABRIC data. Patients with high IL-17 scores had worse overall survival (OS) compared to those with low IL-17 scores. Low IL-17 scores were associated with higher immune checkpoint gene expression and predicted enhanced responses to cytotoxic T-lymphocyte-associated protein 4 (CTLA4) and programmed cell death protein 1 (PD-1) therapies. Patients with low IL-17 scores exhibited a higher abundance of immune microenvironment components. Furthermore, qRT-PCR confirmed the lower expression of <i>OR51E1, NDRG2, RGS2</i>, and <i>TSPAN7</i> in breast tumors compared to normal tissue.</p><p><strong>Conclusions: </strong>IL-17-related signatures are promising biomarkers for predicting the prognosis of IBC patients. These findings suggest that IL-17-related markers could be used to guide individualized therapeutic strategies, potentially improving outcomes for IBC patients.</p>","PeriodicalId":23216,"journal":{"name":"Translational cancer research","volume":"14 2","pages":"907-929"},"PeriodicalIF":1.5,"publicationDate":"2025-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11912043/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143658594","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Androgen receptor expression distribution characteristics in young female breast cancer patients in China: a study of clinicopathological features.","authors":"Jianhong Tu, Xiyan Li, Yuexia Chen, Wei Qu, Dan Gong, Adam Ofri, Rainer J Klement, Swarna Lakshmi Arumugam, Yao Zhou","doi":"10.21037/tcr-2025-147","DOIUrl":"10.21037/tcr-2025-147","url":null,"abstract":"<p><strong>Background: </strong>The expression of androgen receptor (AR) in breast cancer has potential implications for predicting clinical outcomes, especially amongst young female patients. Numerous studies have reported that the co-expression of AR with hormone receptors (HRs) is correlated with a favorable prognosis in breast cancer. However, research on the frequency and distribution of AR expression in Chinese breast cancer patients is limited. This study aims to investigate the relationship between AR expression and the expression of progesterone receptor (PR), estrogen receptor (ER), P53, human epidermal growth factor receptor 2 (HER2), and epidermal growth factor receptor (EGFR) in breast cancer patients, and the distribution of molecular subtypes of breast cancer. Further, we aim to explore the pattern of AR expression and its correlation with clinicopathological features and prognosis among young female patients in China.</p><p><strong>Methods: </strong>Formalin-fixed paraffin-embedded tissue samples from 321 young female breast cancer patients were collected from the Third Hospital of Nanchang. Immunohistochemistry was used to assess the expression of AR, ER, PR, HER2, and Ki67. A statistical analysis was conducted to explore the correlation between the expression of AR and these molecular markers, as well as their distribution across different molecular subtypes of breast cancer, and their prognostic significance.</p><p><strong>Results: </strong>A total of 321 breast cancer patients were included in this study. Significant correlations were found between the positive expression of AR and the high expression of PR and ER (P<0.001). The rate of P53 positivity was significantly higher in the AR-positive patients than the AR-negative patients (P=0.01). Additionally, HER2 expression was significantly higher in the AR-positive patients than the AR-negative patients (P<0.001). Notably, the rate of EGFR positivity was significantly lower in the AR-positive patients compared to AR-negative patients (P<0.001). In relation to the molecular subtypes, AR positivity was significantly associated with the luminal A subtype (P<0.001), while the triple-negative breast cancer (TNBC)/basal-like subtype was more common in the AR-negative patients.</p><p><strong>Conclusions: </strong>This study revealed that in young female breast cancer patients in China, AR-positive breast cancer was significantly associated with the high expression of HRs, increased P53 expression and reduced EGFR expression. The expression status of AR can serve as a biomarker to predict therapeutic responses but could also influence the classification of molecular subtypes and the selection of treatment strategies.</p>","PeriodicalId":23216,"journal":{"name":"Translational cancer research","volume":"14 2","pages":"1388-1400"},"PeriodicalIF":1.5,"publicationDate":"2025-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11912052/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143658627","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The prognostic significance of fragile X mental retardation syndrome-related protein 1 (FXR1) in breast cancer.","authors":"Ohud A Alsalmi, Abrar I Aljohani, Afaf A Alharthi, Amal F Gharib, Abdulrahman R Alrubayee, Ramy M Abbas, Meshari A Alsuwat, Khalid J Alzahrani, Batool S Alsaleh","doi":"10.21037/tcr-24-1542","DOIUrl":"10.21037/tcr-24-1542","url":null,"abstract":"<p><strong>Background: </strong>Breast cancer (BC) is a highly heterogeneous disease with variable histological appearance, biological features, clinical outcomes, and treatment responses. The number of BC cases in Saudi Arabia has more than tripled during the last 17 years to constitute 30% of all cancer cases in women. Therefore, greater efforts are needed to evaluate prognostic factors for BC in Saudi Arabia to improve prognostication and provide more personalized therapy. Recently, fragile X mental retardation syndrome-related protein 1 (FXR1) was identified as a novel biomarker that contributes to oncogenesis; however, its role in BC has not been well studied. This study aims to evaluate the clinicopathological significance of FXR1 in women with primary BC.</p><p><strong>Methods: </strong>The protein levels of FXR1 in BC tissue samples (n=100) were determined immunohistochemically. The associations between FXR1 levels and clinicopathological parameters and outcomes were evaluated, and significant associations were validated by assessing <i>FXR1</i> mRNA levels in publicly available cohorts in the BC Gene-Expression Miner database (version 5).</p><p><strong>Results: </strong>High protein levels of <i>FXR1</i> were significantly associated with tumor aggressiveness, including stage IIB and IIIC and hormone receptor negativity, the triple-negative BC (TNBC) subtype, and poor outcomes. Consistent with the protein results, high mRNA levels of FXR1 were significantly associated with hormone receptor negativity and the TNBC subtype.</p><p><strong>Conclusions: </strong>This study revealed that FXR1 is a prognostic factor for poor prognosis in women with BC. Further functional studies are needed to confirm its role in aggressive BC and its value as a therapeutic target.</p>","PeriodicalId":23216,"journal":{"name":"Translational cancer research","volume":"14 2","pages":"980-989"},"PeriodicalIF":1.5,"publicationDate":"2025-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11912039/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143658637","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Vanillic acid inhibits TGF-β type I receptor to protect bone marrow mesenchymal stem cells from radiation-induced bystander effects.","authors":"Ting Zhou, Yi-Ming Zhang, Gu-Cheng Zhou, Fu-Xian Liu, Zhi-Ming Miao, Li-Ying Zhang, Yang-Yang Li, Zhi-Wei Liu, Shang-Zu Zhang, Jing Li, Fan Niu, Yan Chen, Yong-Qi Liu","doi":"10.21037/tcr-24-1080","DOIUrl":"10.21037/tcr-24-1080","url":null,"abstract":"<p><strong>Background: </strong>Radiotherapy is a major treatment option for non-small cell lung cancer (NSCLC); however, irradiated tumor cells can damage non-irradiated cells through radiation-induced bystander effects (RIBE), which can affect the therapeutic efficacy. The study aimed to investigate the mechanism underlying RIBE and the protective effects of vanillic acid (VA) on human bone marrow mesenchymal stem cells (BMSCs).</p><p><strong>Methods: </strong>We established two irradiation models to investigate RIBE. First, we established the A549 cell irradiation model alone, and tested the expression of cathepsin B (CTSB) and transforming growth factor-beta 1 (TGF-β1) by western blot and immunofluorescence staining. Next, we established a co-culture model of A549 cells and BMSCs. After 2 Gy X-rays irradiation of A549 cells, BMSCs cell viability was detected using Cell Counting Kit-8 (CCK-8), reactive oxygen species (ROS) level was detected using flow cytometry, and CTSB, TGF-β type I receptor (TGFβRI), p62 (sequestosome 1), BECLIN1, microtubule-associated protein light chain 3 (LC3), etc., were detected using western blot. Phosphorylated histone H2AX (γH2AX), CTSB, lysosomal-associated membrane protein 1 (LAMP1), and TGFβRI expression levels were detected by immunofluorescence staining. Molecular docking and molecular dynamics simulation, and a CCK-8 assay were used to screen for molecules from <i>Astragalus membranceus</i> that inhibited TGFβRI activity, to protect BMSCs from RIBE. Lastly, we validated VA activity <i>in vivo</i>.</p><p><strong>Results: </strong>In this study, 2 Gy X-rays radiation on A549 cells was found to result in an increase in CTSB and TGF-β1, while CTSB inhibitor CA074Me reduced the radiation-induced TGF-β1 increase. In the co-culture model of A549 cells and BMSCs, 2 Gy X-rays radiation on A549 cells resulted in increase of TGFβRI expression in BMSCs, which led to an increase in ROS, and resulted in DNA damage and the inhibition of BMSCs proliferation. The small molecule VA from <i>Astragalus membranaceus</i> inhibited TGFβRI activity and restored the proliferation of BMSCs.</p><p><strong>Conclusions: </strong>Our findings reveal that radiation causes CTSB overexpression in A549 cells, which further promotes TGF-β1 expression. TGF-β1 activates its receptors on BMSCs to increase ROS levels in BMSCs, while reducing lysosomal double-chain CTSB (dc-CTSB), which results in decreased BMSCs autophagy and an inability to clear ROS, and thus inhibits proliferation. VA inhibits TGFβRI to restore the proliferation of BMSCs, and <i>in vivo</i>, VA can enhance the killing effect of radiation on tumors.</p>","PeriodicalId":23216,"journal":{"name":"Translational cancer research","volume":"14 2","pages":"1223-1236"},"PeriodicalIF":1.5,"publicationDate":"2025-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11912036/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143658644","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Construction and validation of a cell death-related genes prognosis signature of hepatocellular carcinoma.","authors":"Yue Ma, Che Ismail Che Noh, Rahmawati Pare","doi":"10.21037/tcr-24-1315","DOIUrl":"10.21037/tcr-24-1315","url":null,"abstract":"<p><strong>Background: </strong>The cell death pathway, including apoptosis, autophagy, and necroptosis, plays an essential role in hepatocellular carcinoma (HCC) progression and outcome. However, the integration of the three cell death pathways into a prognostic signature has not yet been reported in HCC. This study aimed to investigate the association among cell death-related genes (CDRGs), prognosis, immune microenvironment, and immune checkpoint.</p><p><strong>Methods: </strong>The RNA expression profiles and corresponding clinical data of HCC were retrieved from The Cancer Genome Atlas (TCGA), Gene Expression Omnibus (GEO), and International Cancer Genome Consortium (ICGC). Univariate Cox regression analysis was performed to identify the relevant prognostic genes, and Lasso Cox regression analysis was employed to calculate the risk score. The relationship between the risk score and clinicopathological characteristics, immune cell infiltration, and immune checkpoint expression was analyzed.</p><p><strong>Results: </strong>A prognostic risk model for HCC was constructed from the identified CDRGs and patients were subgrouped based on risk score. High-risk patients for HCC exhibited a significantly lower overall survival (OS) rate than the low-risk patients. In addition, the receiver operating characteristic (ROC) curve demonstrated the predictive ability of the risk score. Patients in the high-risk group exhibited lower immune cell infiltration and higher expression levels of immune checkpoint molecules.</p><p><strong>Conclusions: </strong>The cell death-related signature established herein provides a valuable predictive tool for survival and holds promise as a potential therapeutic biomarker for HCC.</p>","PeriodicalId":23216,"journal":{"name":"Translational cancer research","volume":"14 2","pages":"1157-1170"},"PeriodicalIF":1.5,"publicationDate":"2025-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11912031/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143658689","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Analysis of risk and prognostic factors for pulmonary metastasis in gastric cancer: a study based on the Surveillance, Epidemiology, and End Results database.","authors":"Wei Kong, Su Yan","doi":"10.21037/tcr-24-2019","DOIUrl":"10.21037/tcr-24-2019","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;Pulmonary metastasis in patients with gastric cancer (GC) is closely associated with adverse clinical outcomes and reduced survival rates. This study aimed to investigate the incidence, risk factors, and prognostic factors of pulmonary metastasis in GC patients.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;A retrospective cohort study was conducted using data from the Surveillance, Epidemiology, and End Results (SEER) database (2010-2021), involving 48,474 GC patients, of whom 2,694 (5.56%) had pulmonary metastasis. Descriptive statistics, multivariable logistic regression, and Cox regression analyses were performed using R software, complemented by Kaplan-Meier survival curves and receiver operating characteristic curve construction.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;Logistic regression revealed that the risk of pulmonary metastasis was significantly higher in patients with squamous cell carcinoma than adenocarcinoma [adjusted odds ratio (aOR) 1.575, 95% confidence interval (CI): 1.152-2.120], while other pathological types showed a lower risk (aOR 0.269, 95% CI: 0.214-0.333). Stage T4 patients had a significantly higher risk than T1 (aOR 1.487, 95% CI: 1.130-1.954). Surgical intervention (aOR 0.198, 95% CI: 0.145-0.265) and clearance of four or more lymph nodes (aOR 0.489, 95% CI: 0.330-0.725) were associated with reduced pulmonary metastasis risks. Conversely, patients with liver, brain, and bone metastases exhibited significantly increased risks of pulmonary metastasis (aOR 3.888, 95% CI: 3.568-4.238; aOR 4.434, 95% CI: 3.480-5.631; and aOR 2.883, 95% CI: 2.568-3.234, respectively). Multivariate Cox regression analysis of overall survival (OS) and cancer-specific survival (CSS) demonstrated that patients with other epithelial tumors had significantly higher mortality risks [hazard ratio (HR) 1.194, 95% CI: 1.019-1.399; HR 1.191, 95% CI: 1.006-1.409]. Conversely, surgical treatment significantly reduced mortality risks (HR 0.632, 95% CI: 0.473-0.843; HR 0.659, 95% CI: 0.486-0.894), as did chemotherapy (HR 0.322, 95% CI: 0.295-0.351; HR 0.336, 95% CI: 0.307-0.369). Single patients (never married) exhibited higher mortality risks (HR 1.142, 95% CI: 1.020-1.278; HR 1.159, 95% CI: 1.030-1.305), as did patients with liver metastasis (HR 1.240, 95% CI: 1.144-1.344; HR 1.275, 95% CI: 1.171-1.388). Patients with primary lesions located in the lower stomach showed increased mortality risk (HR 1.289, 95% CI: 1.110-1.496; HR 1.203, 95% CI: 1.026-1.410), and those with bone metastases also increased OS mortality risk (HR 1.183, 95% CI: 1.071-1.307). The median OS for patients with pulmonary metastasis was 2 months, compared to 14 months for those without (P&lt;0.001).&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusions: &lt;/strong&gt;Surgical treatment and chemotherapy significantly prolonged OS and CSS. Pulmonary metastasis in GC is associated with extremely poor survival rates. Comprehensive screening for high-risk patients, combined with detailed clinical and pathologi","PeriodicalId":23216,"journal":{"name":"Translational cancer research","volume":"14 2","pages":"990-1007"},"PeriodicalIF":1.5,"publicationDate":"2025-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11912073/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143658622","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"High-sensitivity modified Glasgow prognostic score (HS-mGPS) is a prognostic biomarker for small duct-type intrahepatic cholangiocarcinoma-a retrospective cohort study.","authors":"Xintao He, Zixin Liang, Shuo Zhang, Youxiang Ding, Xiaoping Qian, Hongyan Wu, Jun Chen","doi":"10.21037/tcr-24-917","DOIUrl":"10.21037/tcr-24-917","url":null,"abstract":"<p><strong>Background: </strong>Serum biomarkers are often used as part of preoperative prediction strategies to help assess a patient's surgical risk and prognosis. The high-sensitivity modified Glasgow prognostic score (HS-mGPS) has been shown to offer better predictive accuracy compared to the traditional Glasgow prognostic score (GPS) and the modified Glasgow prognostic score (mGPS) in various cancers, but its ability to predict outcomes in patients with resected intrahepatic cholangiocarcinoma (ICC) has not been well-studied. The aim of the study was to investigate the prognostic value of HS-mGPS in ICC and its subtypes.</p><p><strong>Methods: </strong>This study was a single-center retrospective study. All patients who were pathologically diagnosed with ICC after surgery in Nanjing Drum Tower Hospital from 2012 and 2022. Relevant laboratory data such as serum C-reactive protein (CRP), albumin (ALB), neutrophils, lymphocytes, and platelets were included. Overall survival (OS) information was collected, serum CRP and ALB level were used for scoring GPS, mGPS and HS-mGPS. Univariate and multivariate analyses were conducted to identify factors influencing prognosis by using Kaplan-Meier (KM) curve and Cox proportional hazards models. Additionally, through histological analysis, ICC was classified into large duct type (LD-type) and small duct type (SD-type), and the performance of the three scoring systems in these subtypes was examined.</p><p><strong>Results: </strong>A total of 185 patients were included in this study, 57 cases were of the LD-type, and 128 cases were of the SD-type. Tumor subtypes was a significant factor influencing prognosis for all ICC patients [hazard ratio (HR) =1.76, 95% confidence interval (CI): 1.036-2.994, P=0.04]. HS-mGPS demonstrated a better ability to predict outcomes compared to GPS and mGPS, and was an independent prognostic factor of OS (HR =2.1, 95% CI: 1.001-4.374, P=0.049). HS-mGPS was also more effective in predicting prognosis for SD-type ICC compared to GPS and mGPS (HR =3.13, 95% CI: 1.018-9.604, P=0.046), while it was ineffective for LD-type ICC. Further analysis revealed that SD-type ICC with higher HS-mGPS scores typically had larger tumors and poorer differentiation, while LD-type ICC showed no significant differences.</p><p><strong>Conclusions: </strong>HS-mGPS provides a more accurate prognostic indication for SD-type, but its effectiveness for LD-type requires further investigation with larger sample sizes. Therefore, for preoperatively biopsy-diagnosed SD-type ICC, the HS-mGPS has a certain level of prognostic predictive potential.</p>","PeriodicalId":23216,"journal":{"name":"Translational cancer research","volume":"14 2","pages":"1297-1310"},"PeriodicalIF":1.5,"publicationDate":"2025-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11912074/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143657227","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nomogram for predicting survival in breast cancer with lung metastasis based on SEER data.","authors":"Cheng-Liang Chen, Ni-Ya Chen, Shuo Wu, Xiao Lin, Xin-Wei He, Ying Qiu, Di-Xin Xue, Jie Li, Meng-Die He, Xi-Xi Dong, Wei-Ya Zhuang, Mei-Zhen Liang","doi":"10.21037/tcr-24-1047","DOIUrl":"10.21037/tcr-24-1047","url":null,"abstract":"<p><strong>Background: </strong>The incidence of breast cancer (BC) has been steadily increasing, highlighting the need for a predictive model to assess the survival prognosis of BC patients. The objective of this research was to formulate a prognostic nomogram framework tailored to forecast survival among individuals diagnosed with BC with lung metastasis (BCLM).</p><p><strong>Methods: </strong>Our information was sourced from the Surveillance, Epidemiology, and End Results (SEER) database. Individuals who were diagnosed with BC from 2010 to 2015 were selected. The 4,309 collected participants were randomly separated into a training cohort (n=3,231) and a validation cohort (n=1,078). In this study, age, marital status, race, tumor location, laterality, type of primary surgery, surgical margin, tumor grade, tumor (T) stage, node (N) stage, as well as the use of radiotherapy and chemotherapy, were identified as potential prognostic factors. The overall survival (OS) and breast cancer-specific survival (CSS) were defined as the primary endpoints of this study. Univariate and multivariate analyses were conducted to assess the impact of different factors on prognosis. Structured nomograms were developed to improve the prediction of OS and CSS. The concordance index (C-index), receiver operating characteristic (ROC) curves, calibration curves, and decision curve analysis (DCA) were employed to estimate the performance of the nomogram.</p><p><strong>Results: </strong>The nomograms incorporated age, marital status, race, primary surgery or not, BC subtype, grade, T stage, and the use of chemotherapy or not. The C-index for OS was 0.77, and it was 0.77 in CSS for the training group. The C-indexes for the control group of OS and CSS prediction were 0.78 and 0.78, respectively. ROC curves, calibration plots, and DCA curves displayed excellent predictive validity. The results indicate a median survival time of 1.67 years [95% confidence interval (CI): 1.58-1.83], with a total of 3,640 deaths recorded. Survival time was found to be associated with factors such as age, marital status, race, whether primary site surgery was performed, BC subtype, tumor grade, T stage, and the administration of chemotherapy.</p><p><strong>Conclusions: </strong>Nomograms were created to predict OS and CSS for individuals diagnosed with BCLM. The nomogram has a reliable and valid prediction power; it could perhaps assist physicians in calculating patients' mortality risk.</p>","PeriodicalId":23216,"journal":{"name":"Translational cancer research","volume":"14 2","pages":"808-826"},"PeriodicalIF":1.5,"publicationDate":"2025-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11912048/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143658323","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}